Beta Drugs (BETA) Q2 FY27 Profit Rises 16.9% Sequentially Despite Revenue Dip
The pharma firm's net profit grew sequentially on sharper margins, though revenue was down sharply from a high base a year ago.
Beta Drugs posted a Q2 FY27 net profit of ₹19.28 crore, up 16.9% from the previous quarter. Revenue of ₹137.49 crore declined 32.5% year-on-year but improved 9.5% sequentially, with margins expanding.
Beta Drugs, a specialist in oncology and potent formulations, delivered a quarter where profitability strengthened even as the top line faced a tough comparison. The company's net profit grew sequentially on the back of significantly improved margins, a sign of operating efficiency that is central to its current story.
The numbers tell a story of two different timelines. Year-on-year, revenue fell 32.5% to ₹137.49 crore, while profit declined 19.4% to ₹19.28 crore. Sequentially, however, revenue grew 9.5% and profit jumped 16.9%. The net profit margin rose to 14.0%, a 230 basis point improvement from the same quarter last year.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Period | Sep 2026 | Jun 2026 | Sep 2025 |
| Revenue (₹ Cr) | 137.49YoY -32% | 125.55 | 203.59 |
| Profit (₹ Cr) | 19.28YoY -19% | 16.49 | 23.92 |
| Net Profit Margin (%) | 14.0YoY +20% | 13.1 | 11.7 |
Why Margins Expanded
The year-on-year decline in revenue is largely a base effect from an exceptionally strong Q2 FY26. The more telling story is the margin expansion. According to Tradebrains, the company's gross margin widened by 486 basis points in the first half of FY27, driven by higher realizations across businesses. Management has attributed this to cost-reduction initiatives and backward integration, which are expected to support margins going forward.
The Growth Engines
While consolidated revenue was softer, key segments showed robust underlying growth. The Branded Oncology segment grew 17% during H1 FY27, as reported by Tradebrains, though sales were affected by production shutdowns for capacity expansion. The Contract Manufacturing (CMO) business grew 21%, and the export business rebounded sharply with 95% growth in the quarter. The Nivian brand, focused on IVF, delivered 75% growth in the first half.
The Outlook and What It Hinges On
Management has reiterated its full-year guidance, expecting FY27 revenue of ₹535 crore or more with an EBITDA margin of 23–24%, as noted in multiple reports. This implies a significantly stronger second half. The company plans two new Nivian launches in H2 and expects delayed orders from supply constraints to be fulfilled. A new API capacity is also slated to go onstream in Q4 FY27, which should aid backward integration and margins.
Live Chart
· BETA
(BSE)
ISIN: INE351Y01019
Key Points
- Net profit grew 16.9% quarter-on-quarter to ₹19.28 crore, with the net profit margin improving to 14%.
- Revenue of ₹137.49 crore declined year-on-year from a high base but showed a 9.5% sequential recovery.
- Strong margin expansion was driven by better realizations, cost initiatives, and a favorable business mix.
- Segments like exports, CMO, and the Nivian brand reported high double-digit growth, pointing to diversified momentum.
- The company maintains its FY27 revenue guidance of ₹535+ crore, banking on a stronger second-half performance.
Hexa Perspective
The quarter underscores a transition towards higher-quality earnings at Beta Drugs. The ability to expand margins significantly, even on a softer revenue base, suggests improved pricing power and operational discipline. The guidance for a much stronger second half is ambitious and hinges on the timely execution of new launches, fulfillment of delayed orders, and the commissioning of new capacity.
Investors are essentially weighing the demonstrated margin strength against the execution risk embedded in the steep second-half ramp-up. The stock's 14% jump on results day, as reported by Tradebrains, reflects optimism that the margin story can sustain while growth reaccelerates.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.